Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
6.52
Dollar change
+0.95
Percentage change
17.06
%
IndexRUT P/E- EPS (ttm)-0.79 Insider Own42.66% Shs Outstand29.61M Perf Week63.82%
Market Cap193.06M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float16.98M Perf Month41.74%
Income-23.02M PEG- EPS next Q-0.05 Inst Own6.91% Short Float3.85% Perf Quarter8.67%
Sales0.00M P/S- EPS this Y- Inst Trans474.90% Short Ratio4.45 Perf Half Y15.81%
Book/sh0.01 P/B436.70 EPS next Y- ROA-723.88% Short Interest0.65M Perf Year-
Cash/sh0.03 P/C232.60 EPS next 5Y- ROE-1757.27% 52W Range3.11 - 20.72 Perf YTD30.40%
Dividend Est.- P/FCF- EPS past 5Y- ROI-5207.63% 52W High-68.53% Beta-
Dividend TTM- Quick Ratio1.74 Sales past 5Y0.00% Gross Margin- 52W Low109.65% ATR (14)0.61
Dividend Ex-Date- Current Ratio1.74 EPS Y/Y TTM-453.88% Oper. Margin- RSI (14)70.90 Volatility16.55% 14.08%
Employees9 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom- Target Price12.15
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-250.00% Payout- Rel Volume2.44 Prev Close5.57
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsNov 27 Avg Volume147.10K Price6.52
SMA2047.01% SMA5038.28% SMA20017.42% Trades Volume359,253 Change17.06%
Dec-03-24 07:30AM
Nov-21-24 07:00AM
Sep-26-24 04:00PM
Sep-04-24 07:30AM
Aug-20-24 07:30AM
08:30AM Loading…
Aug-12-24 08:30AM
Jul-02-24 08:30AM
Jun-17-24 04:10PM
May-30-24 08:30AM
May-24-24 09:30AM
May-16-24 09:30AM
May-13-24 10:53PM
May-07-24 03:02PM
Apr-16-24 08:30AM
Apr-02-24 08:30AM
04:44PM Loading…
Mar-29-24 04:44PM
Mar-26-24 08:30AM
Mar-22-24 08:30AM
Mar-14-24 08:30AM
Mar-07-24 08:30AM
Mar-05-24 08:30AM
Feb-13-24 04:05PM
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm's initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bay Shore Trust10% OwnerFeb 13 '24Buy7.00138,000966,0005,455,431Feb 15 04:11 PM